Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Atovaquone associated with increased nocardiosis risk
Molina A et al. Acute Leukemia Forum 2018, Poster Session.
Key clinical point:
Major finding: The incidence of nocardiosis was 2.2% during atovaquone use versus 0.17% prior to its use.
Study details: A retrospective review of records for 986 patients.
Disclosures: Mr. Molina reported having no financial disclosures.
Citation:
Molina A et al. Acute Leukemia Forum 2018, Poster Session.
